Assessment of the tumor-associated trypsin inhibitor (TATI) marker in patients with carcinoma of the uterine body 17 years after treatment

On the basis of literature review, the structure of the tumor-associated trypsin inhibitor (TATI) marker and its usefulness in diagnosing and monitoring of various malignant neoplasms has been described. The authors’ own experiences are presented stemming from evaluation of TATI levels in a group of 305 patients suffering from carcinoma of the uterine body, who were primarily operated and then subjected to supplementary therapy in the Center of Oncology in Warsaw, classified in accordance with the FIGO 1988 protocol in the years 1994-1995, and who were observed for 17 years after discontinuation of treatment. A statistical analysis of the level of the TATI marker was carried out in the group of patients with unfavorable prognostic factors, that is the presence of cancerous infiltration in the uterine body, also found in the parametrium, ovaries, as well as diagnosed metastases to the lymphatic nodes found on the basis of post- operative histopathological protocol. The marker was determined three to seven times in serum after each stage of supplementary treat-ment, and at the beginning of the follow-up. Strong significance and elevation of the TATI marker were affirmed for the mean of four initial collections in patients, who had a relapse or metastases within one month to 11 years after termination of therapy.

Neoplastic markers; TATI; PSTI; Prognostic factors; Endometrial carcinoma.

[1] Stenman U.H., Huhtala M.L., Koistinen R., Seppala M.: “Immunohistochemical demonstration of an ovarian cancer associated urinary peptide”. Int. J. Cancer, 1982, 30, 53.

[2] Duffy M.J.: “Prognostic and predictive markers in cancer”. J. Clin. Lig. Assay., 1999, 22, 331.

[3] SPINK1 serine peptidase inhibitor, Kazal type 1 [Homo sapiens], Gene ID: 6690, http://www.ncbi.nlm.nih.gov/gene/6690, date of entry: 10. 07.2012.

[4] Stenman U.H.: “Tumor-associated Trypsin Inhibitor2”. Clin. Chem., 2002, 48, 1206.

[5] Huhtala M.L., Pesonen K., Kalkkinen N., Stenman U.H.: “Purification and characterization of a tumor- associated trypsin inhibitor from the urine of a patient with ovarian cancer”. J. Biol. Chem., 1982, 257, 13713.

[6] Stenman U.H., Huhtala M.L., Koistinen R., Seppälä M.: “Immunochemical demonstration of an ovarian cancer-associated urinary peptide”. Int. J. Cancer, 1982, 30, 53.

[7] Stenman U.H., Koivunen E., Itkonen O., Halila H.: “Clinical use and biological function of tumor associated trypsin inhibitor (TATI)”. Torino: Edizioni Minerva Medica S.P.A., 1993, 351.

[8] Marchbank T., Weaver G., Nilsen-Hamilton M., Playford R.J.: “Pancreatic secretory trypsin inhibitor is a major motogenic and protective factor in human breast milk”. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296, G697. doi: 10.1152/ajpgi.90565.2008. Epub 2009 Jan 15.

[9] Marchbank T., Mahmood A., Fitzgerald A.J., Domin J., Butler M., Goodlad R.A., et al.: “Human pancreatic secretory trypsin inhibitor stabilizes intestinal mucosa against noxious agents”. Am. J. Pathol., 2007, 171, 1462.

[10] Huhtala M.L., Kahanpää K., Seppälä M., Halila H. Stenman U.H.: “Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy”. Int. J. Cancer, 1983, 31, 711.

[11] Halila H., Lehtovirta P., Stenman U.H., Seppälä M.: “CA 125 in the follow-up of patients with ovarian cancer”. Acta Obstet. Gynecol. Scand., 1988, 67, 53.

[12] Peters-Engl C., Medl M., Ogris E., Leodolter S.: “Tumor- associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer”. Anticancer Res., 1995, 15, 2727.

[13] Patton P.E., Field C.S., Harms R.W., Coulam C.B.: “CA125 levels in endometriosis”. Fertil. Steril., 1986, 45, 770.

[14] Barbieri R.L., Niloff J.M., Bast R.C. Jr., Schaetzl E., Kistner R.W., Knapp R.C.: “Elevated serum concentrations of CA125 in patients with advanced endometriosis”. Fertil. Steril., 1986, 45, 630.

[15] Järvisalo J., Hakama M., Knekt P., Stenman U.H., Leino A., Teppo L., et al.: “Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening”. Cancer, 1993, 71, 1982.

[16] Sjöström J., Alfthan H., Joensuu H., Stenman U.H., Lundin J., Blomqvist C.: “Serum tumour markers CA 15-3, TPA, TPS, hCG and TATI in the monitoring of chemotherapy response in metastatic breast cancer”. Scand. J. Clin. Lab. Invest., 2001, 61, 431.

[17] Paju A., Hotakainen K., Cao Y., Laurila T., Gadaleanu V., Hemminki A. et al.: “Increased expression of tumor associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells”. Eur. Urol., 2007, 52, 1670.

[18] Pectasides D., Bafaloucos D., Antoniou F., Gogou L., Economides N., Varthalitis J, et al.: “TPA, TATI, CEA, AFP, HCG, PSA, SCC, and CA19-9 for monitoring transitional cell carcinoma of the bladder”. Am. J. Clin. Oncol., 1996, 19, 271.

[19] Taccone W., Mazzon W., Belli M.: “Evaluation of TATI and other markers in solid tumors”. Scand. J. Clinic. Laborat. Invest., 1991, 207, 25.

[20] Satake K., Inui A., Sogabe T., Yoshii Y., Nakata B., Tanaka H., et al.: “The measurement of serum immunoreactive pancreatic secretory trypsin inhibitor in gastrointestinal cancer and pancreatic disease”. Int. J. Pancreatol. 1988, 3, 323.

[21] Pasanen P., Eskelinen M., Kulju A., Penttila I., Janatuinen E., Alhava E.: “Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242”. Scand. J. Clin. Lab. Invest., 1995, 55, 119.

[22] Solakidi S., Dessypris A., Stathopoulos G.P., Androulakis G., Sekeris C. E: “Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies”. Clin. Biochem., 2004, 37, 56.